Synthesis and pharmacokinetic study of a 11C-labeled cholesterol 24-hydroxylase inhibitor using ‘in-loop’ [11C]CO2 fixation method
作者:Zhen Chen、Jiahui Chen、Natalia Mast、Jian Rong、Xiaoyun Deng、Tuo Shao、Hualong Fu、Qingzhen Yu、Jiyun Sun、Yihan Shao、Lee Josephson、Thomas Lee Collier、Irina Pikuleva、Steven H. Liang
DOI:10.1016/j.bmcl.2020.127068
日期:2020.5
Cholesterol 24-hydroxylase, also known as CYP46A1 (EC 1.14.13.98), is a monooxygenase and a member of the cytochrome P450 family. CYP46A1 is specifically expressed in the brain where it controls cholesterol elimination by producing 24S-hydroxylcholesterol (24-HC) as the major metabolite. Modulation of CYP46A1 activity may affect Aβ deposition and p-tau accumulation by changing 24-HC formation, which
胆固醇24-羟化酶,也称为CYP46A1(EC 1.14.13.98),是一种单加氧酶,是细胞色素P450家族的成员。CYP46A1在脑中特异性表达,它通过产生24S-羟基胆固醇(24-HC)作为主要代谢产物来控制胆固醇的消除。CYP46A1活性的调节可通过改变24-HC的形成来影响Aβ沉积和p-tau积累,此后可作为治疗阿尔茨海默氏病的潜在途径。在这项工作中,我们展示了用于正电子发射断层扫描的新型胆固醇24-羟化酶抑制剂1的有效合成和初步药代动力学评估。